• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在诊断胰腺导管腺癌前数月的代谢和软组织变化阶段。

Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma.

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Department of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, Florida.

出版信息

Gastroenterology. 2019 May;156(6):1742-1752. doi: 10.1053/j.gastro.2019.01.039. Epub 2019 Jan 22.

DOI:10.1053/j.gastro.2019.01.039
PMID:30677401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6475474/
Abstract

BACKGROUND & AIMS: Identifying metabolic abnormalities that occur before pancreatic ductal adenocarcinoma (PDAC) diagnosis could increase chances for early detection. We collected data on changes in metabolic parameters (glucose, serum lipids, triglycerides; total, low-density, and high-density cholesterol; and total body weight) and soft tissues (abdominal subcutaneous fat [SAT], adipose tissue, visceral adipose tissue [VAT], and muscle) from patients 5 years before the received a diagnosis of PDAC.

METHODS

We collected data from 219 patients with a diagnosis of PDAC (patients) and 657 healthy individuals (controls) from the Rochester Epidemiology Project, from 2000 through 2015. We compared metabolic profiles of patients with those of age- and sex-matched controls, constructing temporal profiles of fasting blood glucose, serum lipids including triglycerides, cholesterol profiles, and body weight and temperature for 60 months before the diagnosis of PDAC (index date). To construct the temporal profile of soft tissue changes, we collected computed tomography scans from 68 patients, comparing baseline (>18 months before diagnosis) areas of SAT, VAT, and muscle at L2/L3 vertebra with those of later scans until time of diagnosis. SAT and VAT, isolated from healthy individuals, were exposed to exosomes isolated from PDAC cell lines and analyzed by RNA sequencing. SAT was collected from KRASG12D P53 mice with PDACs, C57/BL6 (control) mice, and 5 patients and analyzed by histology and immunohistochemistry.

RESULTS

There were no significant differences in metabolic or soft tissue features of patients vs controls until 30 months before PDAC diagnosis. In the 30 to 18 months before PDAC diagnosis (phase 1, hyperglycemia), a significant proportion of patients developed hyperglycemia, compared with controls, without soft tissue changes. In the 18 to 6 months before PDAC diagnosis (phase 2, pre-cachexia), patients had significant increases in hyperglycemia and decreases in serum lipids, body weight, and SAT, with preserved VAT and muscle. In the 6 to 0 months before PDAC diagnosis (phase 3, cachexia), a significant proportion of patients had hyperglycemia compared with controls, and patients had significant reductions in all serum lipids, SAT, VAT, and muscle. We believe the patients had browning of SAT, based on increases in body temperature, starting 18 months before PDAC diagnosis. We observed expression of uncoupling protein 1 (UCP1) in SAT exposed to PDAC exosomes, SAT from mice with PDACs, and SAT from all 5 patients but only 1 of 4 controls.

CONCLUSIONS

We identified 3 phases of metabolic and soft tissue changes that precede a diagnosis of PDAC. Loss of SAT starts 18 months before PDAC identification, and is likely due to browning. Overexpression of UCP1 in SAT might be a biomarker of early-stage PDAC, but further studies are needed.

摘要

背景与目的

识别在胰腺导管腺癌(PDAC)诊断之前发生的代谢异常可能会增加早期检测的机会。我们收集了 219 名 PDAC 患者(患者)和 657 名健康个体(对照)在 2000 年至 2015 年期间的数据,用于研究代谢参数(葡萄糖、血清脂质、甘油三酯;总胆固醇、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇;以及总体重)和软组织(腹部皮下脂肪[SAT]、脂肪组织、内脏脂肪组织[VAT]和肌肉)的变化。我们将患者的代谢谱与年龄和性别匹配的对照进行比较,构建空腹血糖、血清脂质(包括甘油三酯)、胆固醇谱和体重及体温的时间谱,时间为 PDAC 诊断前 60 个月(索引日期)。为了构建软组织变化的时间谱,我们从 68 名患者中收集了计算机断层扫描(CT),比较了 L2/L3 椎骨处 SAT、VAT 和肌肉的基线(>18 个月前诊断)区域与后来的扫描区域,直到诊断时间。从 PDAC 细胞系中分离的外泌体暴露于从 KRASG12D P53 小鼠 PDAC、C57/BL6(对照)小鼠和 5 名患者中分离的 SAT 和 VAT,并通过 RNA 测序进行分析。对 SAT 进行了组织学和免疫组织化学分析。

结果

在 PDAC 诊断前 30 个月之前,患者与对照组之间的代谢或软组织特征没有明显差异。在 PDAC 诊断前 30 至 18 个月(第 1 阶段,高血糖)期间,与对照组相比,相当一部分患者出现了高血糖,而没有软组织变化。在 PDAC 诊断前 18 至 6 个月(第 2 阶段,恶病质前期)期间,患者的高血糖和血清脂质、体重和 SAT 显著增加,而 VAT 和肌肉保持不变。在 PDAC 诊断前 6 至 0 个月(第 3 阶段,恶病质)期间,与对照组相比,相当一部分患者出现了高血糖,所有血清脂质、SAT、VAT 和肌肉均显著减少。我们认为患者在 PDAC 诊断前 18 个月开始出现体温升高,这表明 SAT 发生了褐变。我们观察到暴露于 PDAC 外泌体的 SAT、PDAC 小鼠的 SAT 和所有 5 名患者的 SAT 中 UCP1 的表达,但只有 4 名对照中的 1 名。

结论

我们确定了在 PDAC 诊断之前存在 3 个代谢和软组织变化阶段。SAT 的丢失始于 PDAC 识别前 18 个月,可能是由于褐变。SAT 中 UCP1 的过度表达可能是早期 PDAC 的生物标志物,但需要进一步研究。

相似文献

1
Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma.在诊断胰腺导管腺癌前数月的代谢和软组织变化阶段。
Gastroenterology. 2019 May;156(6):1742-1752. doi: 10.1053/j.gastro.2019.01.039. Epub 2019 Jan 22.
2
Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis.空腹血糖水平可预估胰腺癌的发病前病程和进展。
Gastroenterology. 2018 Aug;155(2):490-500.e2. doi: 10.1053/j.gastro.2018.04.025. Epub 2018 Apr 30.
3
Visceral adiposity and inflammatory bowel disease.内脏肥胖与炎症性肠病。
Int J Colorectal Dis. 2021 Nov;36(11):2305-2319. doi: 10.1007/s00384-021-03968-w. Epub 2021 Jun 9.
4
Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling.胰腺导管腺癌恶病质中内脏脂肪组织重塑:激活素 A 信号的作用。
Sci Rep. 2022 Jan 31;12(1):1659. doi: 10.1038/s41598-022-05660-7.
5
Temporal Trends in Body Composition and Metabolic Markers Prior to Diagnosis of Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌诊断前身体成分和代谢标志物的时间趋势。
Clin Gastroenterol Hepatol. 2024 Sep;22(9):1830-1838.e9. doi: 10.1016/j.cgh.2024.03.038. Epub 2024 May 3.
6
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study.腹部内脏和皮下脂肪组织分区:弗雷明汉心脏研究中与代谢危险因素的关联
Circulation. 2007 Jul 3;116(1):39-48. doi: 10.1161/CIRCULATIONAHA.106.675355. Epub 2007 Jun 18.
7
Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy.术前治疗和胰十二指肠切除术对胰腺癌患者人体测量学变化的影响。
J Gastrointest Surg. 2018 Apr;22(4):703-712. doi: 10.1007/s11605-017-3618-4. Epub 2017 Dec 11.
8
Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.胰腺癌恶病质表型、机制和治疗在小鼠和人类中的性别特异性:激活素的作用。
J Cachexia Sarcopenia Muscle. 2022 Aug;13(4):2146-2161. doi: 10.1002/jcsm.12998. Epub 2022 May 5.
9
Subcutaneous adipose tissue in relation to subclinical atherosclerosis and cardiometabolic risk factors in midlife women.中年女性皮下脂肪组织与亚临床动脉粥样硬化及心血管代谢危险因素的关系。
Am J Clin Nutr. 2011 Apr;93(4):719-26. doi: 10.3945/ajcn.110.007153. Epub 2011 Feb 23.
10
Relationship among CT-based abdominal adipose tissue areas and pancreatic ductal adenocarcinoma in male.男性中基于CT的腹部脂肪组织面积与胰腺导管腺癌之间的关系。
Aging Male. 2020 Dec;23(5):1455-1459. doi: 10.1080/13685538.2020.1793940. Epub 2020 Nov 16.

引用本文的文献

1
Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study.血糖定义的新发糖尿病患者患胰腺癌的风险:一项前瞻性队列研究。
Gastroenterology. 2025 Jul 7. doi: 10.1053/j.gastro.2025.06.025.
2
Pancreatic cancer cachexia is mediated by PTHrP-driven disruption of adipose lipogenesis.胰腺癌恶病质由甲状旁腺激素相关蛋白(PTHrP)驱动的脂肪生成破坏介导。
bioRxiv. 2025 Jun 7:2025.06.03.657464. doi: 10.1101/2025.06.03.657464.
3
Imaging Cancer-associated Cachexia: Utilizing Clinical Imaging Modalities for Early Diagnosis.影像诊断癌症相关性恶病质:利用临床影像模态进行早期诊断
Radiol Imaging Cancer. 2025 Jul;7(4):e240291. doi: 10.1148/rycan.240291.
4
Can AI Be Useful in the Early Detection of Pancreatic Cancer in Patients with New-Onset Diabetes?人工智能在新发糖尿病患者胰腺癌的早期检测中是否有用?
Biomedicines. 2025 Mar 31;13(4):836. doi: 10.3390/biomedicines13040836.
5
Insulin resistance and cancer: molecular links and clinical perspectives.胰岛素抵抗与癌症:分子联系及临床展望
Mol Cell Biochem. 2025 Mar 15. doi: 10.1007/s11010-025-05245-8.
6
Artificial neural network detection of pancreatic cancer from proton (1H) magnetic resonance spectroscopy patterns of plasma metabolites.基于血浆代谢物质子(1H)磁共振波谱模式的人工神经网络对胰腺癌的检测
Commun Med (Lond). 2025 Jan 21;5(1):24. doi: 10.1038/s43856-024-00727-0.
7
GRP75 triggers white adipose tissue browning to promote cancer-associated cachexia.GRP75 触发白色脂肪组织棕色化以促进癌症相关性恶病质。
Signal Transduct Target Ther. 2024 Sep 26;9(1):253. doi: 10.1038/s41392-024-01950-w.
8
Prognostic impact of shift to low visceral fat mass after neoadjuvant chemotherapy in patients with esophageal cancer.新辅助化疗后内脏脂肪质量降低对食管癌患者预后的影响。
Cancer Rep (Hoboken). 2024 Aug;7(8):e2084. doi: 10.1002/cnr2.2084.
9
Circulating adipose-tissue miRNAs in gastrointestinal cancer patients and their association with the level and type of adiposity at body composition analysis.胃肠道癌症患者循环脂肪组织中的微小RNA及其与身体成分分析中肥胖水平和类型的关联。
Front Mol Biosci. 2024 Jul 30;11:1449197. doi: 10.3389/fmolb.2024.1449197. eCollection 2024.
10
Emerging mechanisms and promising approaches in pancreatic cancer metabolism.胰腺癌代谢中的新兴机制与前景广阔的方法
Cell Death Dis. 2024 Aug 1;15(8):553. doi: 10.1038/s41419-024-06930-0.

本文引用的文献

1
Altered exocrine function can drive adipose wasting in early pancreatic cancer.外分泌功能改变可导致早期胰腺癌的脂肪消耗。
Nature. 2018 Jun;558(7711):600-604. doi: 10.1038/s41586-018-0235-7. Epub 2018 Jun 20.
2
Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes.用于确定新发糖尿病患者罹患胰腺癌风险的模型。
Gastroenterology. 2018 Sep;155(3):730-739.e3. doi: 10.1053/j.gastro.2018.05.023. Epub 2018 Jun 11.
3
Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis.空腹血糖水平可预估胰腺癌的发病前病程和进展。
Gastroenterology. 2018 Aug;155(2):490-500.e2. doi: 10.1053/j.gastro.2018.04.025. Epub 2018 Apr 30.
4
Caloric Restriction and Diet-Induced Weight Loss Do Not Induce Browning of Human Subcutaneous White Adipose Tissue in Women and Men with Obesity.热量限制和饮食诱导的体重减轻不会诱导肥胖女性和男性皮下白色脂肪组织的棕色化。
Cell Rep. 2018 Jan 23;22(4):1079-1089. doi: 10.1016/j.celrep.2017.12.102. Epub 2018 Jan 28.
5
Immunosuppressive CD14HLA-DR monocytes are elevated in pancreatic cancer and "primed" by tumor-derived exosomes.免疫抑制性CD14 HLA - DR单核细胞在胰腺癌中升高,并被肿瘤来源的外泌体“致敏”。
Oncoimmunology. 2016 Nov 2;6(1):e1252013. doi: 10.1080/2162402X.2016.1252013. eCollection 2017.
6
A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes.一种评估新发糖尿病患者胰腺癌风险的临床预测模型。
Gastroenterology. 2017 Mar;152(4):840-850.e3. doi: 10.1053/j.gastro.2016.11.046. Epub 2016 Dec 5.
7
Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue.胰腺癌外泌体诱导脂肪组织脂解的发病机制。
Gut. 2016 Jul;65(7):1165-74. doi: 10.1136/gutjnl-2014-308350. Epub 2015 Apr 28.
8
A switch from white to brown fat increases energy expenditure in cancer-associated cachexia.由白色脂肪向棕色脂肪的转变可增加癌症恶病质相关的能量消耗。
Cell Metab. 2014 Sep 2;20(3):433-47. doi: 10.1016/j.cmet.2014.06.011. Epub 2014 Jul 17.
9
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features.featureCounts:一个用于将序列读取分配给基因组特征的高效通用程序。
Bioinformatics. 2014 Apr 1;30(7):923-30. doi: 10.1093/bioinformatics/btt656. Epub 2013 Nov 13.
10
Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies.Oncotype DX 前列腺癌检测的分析验证——一种针对前列腺针吸活检优化的临床实时聚合酶链反应检测。
BMC Genomics. 2013 Oct 8;14:690. doi: 10.1186/1471-2164-14-690.